Nomura Healthcare Fund Class R (DLRHX)
| Fund Assets | 705.88M |
| Expense Ratio | 1.46% |
| Min. Investment | $0.00 |
| Turnover | 5.00% |
| Dividend (ttm) | 2.84 |
| Dividend Yield | 11.64% |
| Dividend Growth | -12.92% |
| Payout Frequency | Annual |
| Ex-Dividend Date | Dec 2, 2025 |
| Previous Close | 24.63 |
| YTD Return | -2.34% |
| 1-Year Return | 19.66% |
| 5-Year Return | 55.61% |
| 52-Week Low | 20.83 |
| 52-Week High | 28.39 |
| Beta (5Y) | n/a |
| Holdings | 106 |
| Inception Date | Jan 28, 2010 |
About DLRHX
Macquarie Healthcare Fund Class R is an actively managed mutual fund specializing in the healthcare sector. Its primary function is to provide investors with exposure to a diversified portfolio of companies operating in medical and healthcare industries, including pharmaceuticals, medical device manufacturers, health maintenance organizations (HMOs), hospitals, and nursing homes. The fund aims to capitalize on the significant long-term growth potential within global healthcare markets by investing across multiple segments of the industry, sometimes with a focus on specific sectors such as biotechnology or service providers. Managed by Liu-Er Chen since 2007, the fund leverages deep industry expertise and quantitative analysis to inform its investment decisions. It benchmarks its performance against the Russell 3000 Healthcare Index and is designed for investors seeking targeted healthcare exposure within their broader portfolio allocations. Macquarie Healthcare Fund Class R is notable for its dedicated healthcare focus, relatively low barriers to entry for certain share classes, and a stated net expense ratio of 1.46%. It plays a significant role in offering investors thematic access to the health sector, allowing participation in an industry that often demonstrates resilience and innovation regardless of broader economic cycles.
Performance
DLRHX had a total return of 19.66% in the past year, including dividends. Since the fund's inception, the average annual return has been 13.39%.
Top 10 Holdings
42.12% of assets| Name | Symbol | Weight |
|---|---|---|
| UCB SA | UCB | 5.73% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.07% |
| Pfizer Inc. | PFE | 4.41% |
| Gilead Sciences, Inc. | GILD | 4.34% |
| Eli Lilly and Company | LLY | 4.07% |
| AbbVie Inc. | ABBV | 4.06% |
| Chugai Pharmaceutical Co., Ltd. | 4519 | 3.72% |
| Roche Holding AG | ROG | 3.63% |
| AstraZeneca PLC | AZN | 3.55% |
| Merck & Co., Inc. | MRK | 3.53% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 2, 2025 | $2.84116 | Dec 2, 2025 |
| Dec 3, 2024 | $3.26278 | Dec 4, 2024 |
| Dec 4, 2023 | $1.39633 | Dec 5, 2023 |
| Dec 2, 2022 | $2.274 | Dec 5, 2022 |
| Dec 3, 2021 | $1.476 | Dec 6, 2021 |
| Dec 4, 2020 | $1.496 | Dec 7, 2020 |